MedTrace Logo

Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy

NCT00864331 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 251

Last updated 2013-08-07

No results posted yet for this study

Summary

Primary objectives of the study are:

To assess the differences in survival of the two treatment options in both stage III (A and B) nonsmall cell lung cancer (NSCLC) (Study A) and Stage IIIB (wet) and stage IV NSCLC (Study B), respectively

Secondary objectives are:

To assess the differences in toxicity of two treatment options in both stage III (A and B) NSCLC (Study A) and Stage IIIB (wet) and stage IV NSCLC (Study B), and To assess the differences in Health Related Quality of Life (HRQoL) of two treatment options in both Study A and Study B

Conditions

  • Non Small Cell Lung Cancer

Interventions

RADIATION

radiation

39 Gy in 13 daily fractions of 3 Gy

OTHER

Chemotherapy and radiotherapy

Chemotherapy followed by low dose palliative radiotherapy

DRUG

Chemotherapy

Chemotherapy given alone

OTHER

Palliative radiotherapy and chemotherapy

Low dose palliative radiotherapy followed by chemotherapy

Sponsors & Collaborators

  • International Atomic Energy Agency

    lead OTHER_GOV

Principal Investigators

  • Elena Fidarova, MD · International Atomic Energy Agency

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Chile
  • China
  • Croatia
  • Egypt
  • India
  • Malaysia
  • Malta
  • Morocco
  • Pakistan
  • Panama
  • Peru
  • South Africa
  • Tunisia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00864331 on ClinicalTrials.gov